| Role |
Name |
Disclosure |
Details |
| Author | T Allen Gore, MD, MBA, CMCM, DFAPA, Assistant Professor, Department of Psychiatry, Howard University School of Medicine; Associate Director of Medical Affairs, Saint Elizabeth's Hospital, District of Columbia Department of Mental Health | Nothing to disclose | Details | | Coauthor | Georgianna M Richards-Reid, MD, Staff Physician, Department of Neurology, Howard University Hospital, Howard University College of Medicine | Nothing to disclose | Details | | Medical Editor | Denis F Darko, MD, Executive Director, Clinical Research and Development, Neuroscience Global Licensing Medical Director, Clinical Neuroscience Therapy Area and CNS and Pain Control Research Area, AstraZeneca LP | AstraZeneca | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Iqbal Ahmed, MBBS, Professor, Department of Psychiatry, John A Burns School of Medicine, University of Hawaii | Nothing to disclose | Details | | CME Editor | Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin | lilly BMS Forest Labs AstraZeneca Pfizer Northstar Novartis Pfizer | Details | | Chief Editor | Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Georgianna M Richards-Reid, Coauthor |
The contributor discloses no conflict of interest. |
|